Sijian Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sijian Liao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Jianxia Xiong
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication- Kun Huang
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication - Runlu Hu
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication Wei Li
Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China
1 shared publicationXinli Liu
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication- Xuan Deng
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-14
Genotype–Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
Purpose: To explore genotype–phenotype associations of IL36RN variants and clinical outcomes of spesolimab treatment in acrodermatitis continua of Hallopeau (ACH). Patients and methods: This multicenter retrospective study included 14 ACH patients with IL36RN genotyping from 2019 to 2025. Clinical features were compared across all genotypes. Medical records of individuals who received spesolimab were reviewed to describe treatment responses, with a follow-up observation period up to 56 weeks. Results: Compared with monoallelic or wild-type genotypes, biallelic IL36RN variants were associated with earlier disease onset age (23 vs 48 and 47 years, P < 0.05) and higher baseline disease severity (median GPPGA score, 4 vs 3 and 2, P < 0.001). Among 6 patients with biallelic, refractory ACH who received spesolimab, including 3 isolated cases that were administered at a 450-mg dose, overall percentage improvement across disease activity and patient-reported measures occurred rapidly, reaching 54% at week 1 and 74% at week 4. Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment. Conclusion: Spesolimab was associated with clinical improvement in refractory ACH with biallelic IL36RN mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares.
- 1 July 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-14
Open AccessGenotype–Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
Purpose: To explore genotype–phenotype associations of IL36RN variants and clinical outcomes of spesolimab treatment in acrodermatitis continua of Hallopeau (ACH). Patients and methods: This multicenter retrospective study included 14 ACH patients with IL36RN genotyping from 2019 to 2025. Clinical features were compared across all genotypes. Medical records of individuals who received spesolimab were reviewed to describe treatment responses, with a follow-up observation period up to 56 weeks. Results: Compared with monoallelic or wild-type genotypes, biallelic IL36RN variants were associated with earlier disease onset age (23 vs 48 and 47 years, P < 0.05) and higher baseline disease severity (median GPPGA score, 4 vs 3 and 2, P < 0.001). Among 6 patients with biallelic, refractory ACH who received spesolimab, including 3 isolated cases that were administered at a 450-mg dose, overall percentage improvement across disease activity and patient-reported measures occurred rapidly, reaching 54% at week 1 and 74% at week 4. Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment. Conclusion: Spesolimab was associated with clinical improvement in refractory ACH with biallelic IL36RN mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares.